Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer (DEVELOP)

This study has been completed.
Information provided by (Responsible Party):
Centre of Experimental Medicine, Queen Mary University of London Identifier:
First received: October 17, 2012
Last updated: November 11, 2013
Last verified: November 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2012
  Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)